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a  b  s  t  r  a  c  t
Background:  Aortic  stenosis  (AS)  is  recognized  as a cause  of sudden  cardiac  death.  Recently,  the  mea-
surement  of high-sensitivity  troponin  T (hs-TnT)  has  become  possible.  Several  studies  have  clariﬁed  that
hs-TnT  is  a marker  to indicate  mortality  of cardiovascular  diseases.
Objectives:  To examine  whether  hs-TnT  can  be  used  as a prognostic  marker  to  predict  the  operative
outcome  of AS.
Methods:  We  enrolled  60 patients  with AS  (mean  age =  68.7  ±  9.6  years,  male/female  = 30/30).  Cardiac
catheterization  and  echocardiography  were  performed  to evaluate  the  severity  of  AS. Aortic  valve
replacement  surgery  was  performed  in  all patients.  We  deﬁned  major  adverse  cardiac  events  (MACE)
as  composite  events  of  heart  failure,  fatal  arrhythmia,  and  all causes  of death.
Results: We  followed  up  the  patients  for 922  ±  800  days.  Mean  left  ventricular  ejection  fraction  was
60.0  ±  1.8%.  Mean  aortic  valve  area  was  0.61  ±  0.03  cm2. MACE  occurred  in  11  patients  (18%),  including  5
sudden  cardiac  deaths.  We divided  the patients  into  three  groups  based  on the percentile  of the  plasma
levels  of  hs-TnT.  Kaplan–Meier  curve  revealed  a  statistically  signiﬁcant  difference  in MACE  rate  among
the  groups  (log-rank  test,  2 = 13.0, p =  0.002).  We  conducted  a Cox proportional  hazard  analysis  with  a
model  including  age,  sex, estimated  glomerular  ﬁltration  rate,  and  hs-TnT  tertile  as  explanatory  variables
to predict  MACE.  We  found  that hs-TnT  tertile  to  be a signiﬁcant  factor  to  predict  MACE (hazard  ratio:
3.71,  p  = 0.03).
Conclusions:  hs-TnT  can  be  a prognostic  marker  for patients  with  AS  after  valve  replacement  surgery.
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Aortic stenosis (AS) is associated with a poor prognosis once
ymptoms ensue [1,2]. Commonly, a decision on aortic valve
eplacement for severe AS is based on symptoms such as angina,
yncope, and heart failure. However, there is marked mismatch
etween the onset of symptoms and severity of valvular stenosis.
t makes it difﬁcult to decide optimal operative time and predict
rognosis of AS patients. Therefore, the establishment of a simple
nd objective marker to predict the prognosis of this disorder is
eeded.
Aortic valve replacement (AVR) is the standard treatment
or severe AS, alleviating symptoms and improving survival
3–5]. However, despite the recent development of AVR, critical
ardiovascular events such as fatal arrhythmias and congestive
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heart failure (CHF) remain problematic. The prognosis of patients
with AS who have undergone AVR has improved, but a num-
ber of major adverse cardiovascular events (MACE) especially
cardiac sudden death occur even after AVR. Therefore, the
detection and management of high-risk patients have potential
importance.
Cardiac troponins are ideal biochemical markers for the detec-
tion of myocardial cell injury because of their high-sensitivity
and speciﬁcity, especially as markers of acute coronary syndrome
[6–10]. Minute elevations of cardiac troponin are reported to be
related to cardiovascular risk factors, carotid artery plaque burden,
and myocardial dysfunction [11]. Previously, undetectable cardiac
troponin T concentrations have been documented to contain sub-
stantial diagnostic and prognostic information [12–14]. Recently,
a new high-sensitivity cardiac troponin T (hs-TnT) assay that can
detect low levels of circulating cardiac troponin T has emerged. The
new method makes it possible to measure concentrations >10-fold
lower than the lower limit of the traditional assay. The superior
sensitivity of the new assay currently provides a method that can
detect cardiac troponin T levels in most patients with stable [15]
and subclinical cardiovascular disease [16].






















































patients (43.3%). Twenty-six (43.3%) patients received a mechan-
ical prosthetic and 34 patients, a bioprosthetic valve replacement
according to the operator’s decision. Six (10%) patients underwent
Table 1
Baseline characteristics of the subjects.
Age (mean ± SD, years) 68.7 ± 9.6
Male patients (%) 30 (50)
Body mass index (kg/m2) 23.2 ± 0.5
Hypertension (%) 40 (66.7)
Dyslipidemia (%) 18 (30.0)
Diabetes mellitus (%) 17 (28.3)
Smoking (%) 9 (15.0)
The peak-to-peak PG (mmHg) 77.4 ± 4.0
LVEDVI (mL/m2) 98.0 ± 5.3
LVESVI (mL/m2) 41.4 ± 4.0
LVEF (%) 60.0 ± 1.8
Aortic valve area (cm2) 0.61 ± 0.03
The maximum PG (mmHg) 96.2 ± 3.0
The mean PG (mmHg) 58.8 ± 2.3
LVMI (g/m2) 177.9 ± 8.3
hs-CRP (ng/mL) 2216 ± 686
eGFR (mL/min/1.73 m2) 67.6 ± 3.1
hs-TnT (ng/mL) 0.110 ± 0.088
SD, standard deviation; PG, pressure gradient through aortic valve; LVEDVI, left ven-
tricular end-diastolic volume index; LVESVI, left ventricular end-systolic volumeT. Saito et al. / Journal of 
We  hypothesized that preoperative plasma hs-TnT is related to
ardiovascular events in patient with severe AS who  have under-
one AVR. In this study, we have measured plasma levels of hs-TnT
nd investigated their clinical signiﬁcance in patients with AS.
ubjects and methods
atients
Consecutive patients who underwent AVR for the treatment of
evere AS in Jichi Medical University Hospital between July 2003
nd October 2010 were included in this study. Before AVR, all
atients were subjected to cardiac catheterization and echocar-
iography to estimate the left ventricular ejection fraction (LVEF),
ortic valve area (AVA), and pressure gradient (PG) between the
eft ventricle and aorta. We  conﬁrmed whether they had coro-
ary artery disease, aortic regurgitation, and mitral regurgitation
y cardiac catheterization and echocardiography.
Prosthetic valves were implanted into the aortic valve according
o the operators’ decision. After the AVR, all patients were followed
p regularly every 4–8 weeks. The primary endpoint was the occur-
ence of MACE deﬁned as composite events of re-admission to the
ospital for CHF, fatal arrhythmia, and all causes of death. Fatal
rrhythmia included ventricular tachycardia, ventricular ﬁbrilla-
ion, and complete atrioventricular block.
We excluded patients with coronary artery disease, acute
oronary syndrome, severe aortic regurgitation, combined mitral
alvular disease, acute renal failure, and inoperable patients. Coro-
ary artery disease was deﬁned as evidence of signiﬁcant stenosis
f the epicardial coronary artery on angiograms (over 75% steno-
is in the artery and over 50% stenosis in left main trunk). LVEF
as measured by a modiﬁed Simpson’s method and left ven-
ricular mass and relative wall thickness by standard formulas
y echocardiography. High-sensitivity C-reactive protein (hs-CRP)
as measured by latex nephelometry as described by Ledue et al.
17]. Other biochemical substances were determined by standard
ssays. Hypertension [18], dyslipidemia [19], and diabetes mel-
itus [20] were diagnosed according to the criteria described by
uidelines for each disease. The Ethics Committee of Jichi Medical
niversity approved the study protocol. All patients enrolled in this
tudy provided informed consent.
easurement of plasma high-sensitivity troponin T levels
Peripheral blood was taken from the patients before cardiac
atheterization. Anti-coagulated samples were then centrifuged
mmediately at 1000 × g (4 ◦C, 15 min) and stored at −80 ◦C until the
ssay. The concentration of hs-TnT in plasma was determined using
lectrochemiluminescence immunoassay kits according to the
anufacturer’s instructions (Roche Diagnostics GmbH, Mannheim,
ermany). The test has an analytic range of 0.003–10 ng/mL, and
he 99th percentile cutoff point has been reported as ≥0.014 ng/mL
n healthy individuals [21].
tatistical analysis
All values are expressed as the mean ± SEM unless otherwise
ndicated. The signiﬁcance of differences between the three groups
as determined by a one-way analysis of variance for the para-
etric analysis and the Kruskal–Wallis test for the non-parametric
nalysis. The change in hemodynamic data before and after the
peration was  analyzed using Student’s paired t test. Categorical
ariables were expressed as percentages and analyzed using the
-square test or Fisher’s exact test. Kaplan–Meier survival curve
nd Cox proportional hazard model analyses were conducted withlogy 61 (2013) 342–347 343
computer software (SPSS version 16.0, Chicago, IL, USA). Values of
p < 0.05 were considered signiﬁcant.
Results
Basic characteristics of study subjects
We studied 60 patients (aged 68.7 ± 9.6 years), of whom 30
(50%) were male. The number of patients with chest pain, syn-
cope, and heart failure was  28 (46.7%), 11 (18.3%), and 23 (38.3%),
respectively. Table 1 shows the baseline characteristics of the sub-
jects. The mean plasma hs-TnT level was  higher than that in normal
individuals (≥0.014 ng/mL).
In cardiac catheterization, the average catheter-derived peak-
to-peak PG through the aortic valve, left ventricular end-diastolic
volume index (LVEDVI), and left ventricular end-systolic vol-
ume  index (LVESVI) were 77.4 ± 4.0 mmHg, 98.0 ± 5.3 mL/m2,
and 41.4 ± 4.0 mL/m2, respectively. The left ventricular end-
diastolic pressure and pulmonary capillary wedge pressure were
22.2 ± 1.04 mmHg  and 11.9 ± 0.78 mmHg, respectively. Cardiac
index was  3.09 ± 0.09 L/min/m2. The comparison of echocardiog-
raphic ﬁndings (pre-operation and before discharge) revealed that
the peak PG, mean systolic PG, and left ventricular mass index
decreased signiﬁcantly (from 96.2 ± 3.0 mmHg  to 32.4 ± 1.4 mmHg,
p < 0.001, from 58.8 ± 2.3 mmHg  to 18.5 ± 1.1 mmHg, p < 0.001,
and from 177.9 ± 8.3 g/m2 to 160.5 ± 9.6 g/m2, p < 0.05, respec-
tively) with AVR. The left ventricular end-diastolic diameter
reduced signiﬁcantly (from 47.6 ± 0.99 mm to 43.5 ± 0.80 mm,
p < 0.001), while interventricular septal thickness (IVST) and pos-
terior wall thickness (PWT) did not change signiﬁcantly (IVST:
from 14.2 ± 0.34 mm  to 14.1 ± 0.28 mm,  p = 0.79; PWT: from
13.6 ± 0.28 mm to 13.3 ± 0.24 mm,  p = 0.28). AVA increased signiﬁ-
cantly (from 0.61 ± 0.03 cm2 to 1.13 ± 0.06 cm2, p < 0.001) after the
operation. LVEF did not change signiﬁcantly (from 60.0 ± 1.8% to
62.3 ± 1.6%, p = 0.18).
In operative ﬁndings, bicuspid aortic valves were found in 34
patients (56.7%) and atherosclerotic changes in the remaining 26index; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; hs-
CRP,  high-sensitivity C-reactive protein; eGFR, estimated glomerular ﬁltration rate;
hs-TnT, high-sensitivity troponin T. The peak-to-peak PG, LVEDVI, and LVESVI were
measured by cardiac catheterization. LVEF, aortic valve area, the maximum PG, the






































≥0.014 ng/mL), Kaplan–Meier curve analysis revealed a statistically
signiﬁcant difference in the occurrence of MACE between the two
groups (log-rank test, 2 = 6.24, p = 0.04).
Table 3
Baseline characteristics of the patients divided by hs-TnT tertiles.
hs-TnT tertiles T1 (n = 16) T2 (n = 24) T3 (n = 20)
Age (mean ± SD, years) 68.3 ± 8.5 69.7 ± 7.9 67.8 ± 12.3
Male patient (%) 9 (56.3) 10 (41.7) 11 (55.0)
Chest pain (%) 7 (43.4) 14 (58.3) 7(35.0)
Syncope (%) 3 (18.8) 6 (25.0) 2 (10.0)44 T. Saito et al. / Journal of 
raft replacement of the ascending aorta and one (1.7%) patient
eceived tricuspid annuloplasty, concurrently.
Fig. 1 shows the distribution of plasma hs-TnT in our study
opulation. Mean plasma hs-TnT was 0.110 ng/mL with standard
eviation of 0.682 ng/mL and standard error of 0.088 ng/mL. Max-
mum and minimum values were 0.003 ng/mL and 5.30 ng/mL,
espectively. Median value of hs-TnT was 0.015 ng/mL. We  did not
nd signiﬁcant correlation between plasma levels of hs-TnT and
chocardiographic parameters associated with AS (mean systolic
G through the aortic valve, AVA, IVST, PWT, and left ventri-
ular dimensions). As shown in Table 2, we found signiﬁcant
orrelations between plasma hs-TnT and clinical parameters, age,
spartate aminotransferase, hs-CRP, estimated glomerular ﬁltra-
ion rate (eGFR), and N-terminal pro-B-type natriuretic peptide
NT-pro BNP). We  performed multiple regression analysis using
s-TnT as a responsive variable and age, aspartate aminotrans-
erase, hs-CRP, eGFR, and NT-pro BNP as explanatory variables. We
ound that NT-proBNP was a signiﬁcant variable for plasma hs-TnT
ˇ = +0.67; p < 0.001).
igh-sensitivity troponin T levels as a predictor of MACE
We  examined whether plasma levels of hs-TnT can be used to
redict MACE after AVR. The mean follow-up period was  922 ± 800
14–2300) days. MACE occurred in 11 patients (18.3%). We  divided
he patients into three groups based on the percentile of the
lasma hs-TnT level: 0.003 to <0.011 ng/mL (T1: ﬁrst tertile, n = 16),
.011 to <0.0237 ng/mL (T2: second tertile, n = 24), and 0.0237 to
5.3 ng/mL (T3: third tertile, n = 20). The mean level of hs-TnT
ig. 1. Distribution of plasma high-sensitivity troponin T (hs-TnT). The ﬁgure shows
istribution of plasma levels of hs-TnT (logarithmic transformed) of study popula-
ion by histogram. Mean plasma hs-TnT was 0.110 ng/mL with standard deviation
f  0.682 ng/mL and standard error of 0.088 ng/mL. Maximum and minimum values
ere 0.003 and 5.30 ng/mL, respectively. Median value of hs-TnT was 0.015 ng/mL.
ashed line shows the cutoff point determined by normal individuals (0.013 ng/mL).
able 2




Age (years) −0.261 0.04
Aspartate aminotransferase (IU/L) +0.266 0.04
hs-CRP (logarithmic transformed, ng/mL) +0.280 0.03
eGFR (mL/min/1.73 m2) −0.560 <0.001
NT-pro BNP (logarithmic transformed, pg/mL) +0.756 <0.001
s-TnT, high-sensitivity troponin T; hs-CRP, high-sensitivity C reactive protein;
GFR, estimated glomerular ﬁltration rate; NT-pro BNP, N-terminal pro-brain natri-
retic peptide.logy 61 (2013) 342–347
in T1, T2, and T3 was 0.007 ± 0.001 ng/mL, 0.015 ± 0.001 ng/mL,
and 0.306 ± 0.263 ng/mL, respectively. Table 3 shows the base-
line clinical characteristics of the subjects in the groups and the
patients divided by hs-TnT tertiles, respectively. The incidence
of heart failure in T2 and T3 was  signiﬁcantly higher compared
with that in T1 before the operation. The eGFR was signiﬁcantly
lower in T3 than that in T1. As shown in Fig. 2, Kaplan–Meier
curves revealed a statistically signiﬁcant difference in the occur-
rence of MACE among the three groups (log-rank test, 2 = 13.0,
p = 0.002). Post hoc analysis revealed that the incidence of MACE
was signiﬁcantly different between T1 and T3 (p = 0.01) and T2
and T3 (p = 0.01). We  summarized the cardiovascular events in the
three groups (Table 4). When we divided patients into two  groups
according to the normal value of plasma hs-TnT (<0.014 mg/mL  orHeart failure (%) 2 (13.1) 11 (45.8)* 10 (50.0)*
Body mass index (kg/m2) 22.7 ± 0.8 23.7 ± 0.9 23.1 ± 0.7
Hypertension (%) 9 (56.3) 16 (66.7) 15 (75.0)
Dyslipidemia (%) 3 (18.8) 9 (37.5) 6 (30.0)
Diabetes mellitus (%) 3 (18.8) 8 (33.3) 6 (30.0)
Current smoker (%) 2 (12.5) 3 (12.5) 4 (20.0)
Peak-to-peak PG (mmHg) 83.3 ± 5.1 75.2 ± 5.7 87.1 ± 7.4
LVEDVI (mL/m2) 83.7 ± 6.5 106.6 ± 10.8 98.5 ± 7.0
LVESVI (mL/m2) 27.7 ± 1.9 43.4 ± 7.5 49.3 ± 6.9
LVEF (%) 66.8 ± 2.2 58.5 ± 3.0 56.4 ± 3.3
Aortic valve area (cm2) 0.58 ± 0.05 0.67 ± 0.05 0.54 ± 0.05
The maximum PG (mmHg) 103.3 ± 4.9 95.7 ± 5.3 91.2 ± 5.1
The mean PG (mmHg) 61.9 ± 3.9 61.2 ± 4.5 54.3 ± 3.4
LVMI (g/m2) 161.3 ± 15.2 180 ± 11.5 187 ± 16.8
hs-CRP (ng/mL) 1339 ± 676 1581 ± 729 3678 ± 1777
eGFR (mL/min/1.73 m2) 76.1 ± 3.9 71.8 ± 2.7 55.7 ± 7.6*
hs-TnT (ng/mL) 0.007 ± 0.001 0.015 ± 0.001* 0.306 ± 0.263**
hs-TnT, high-sensitivity troponin T; SD, standard deviation; PG, pressure gradient
through aortic valve; LVEDVI, left ventricular end-diastolic volume index; LVESVI,
left  ventricular end-systolic volume index; LVEF, left ventricular ejection fraction;
LVMI, left ventricular mass index; hs-CRP, high-sensitivity C-reactive protein; eGFR,
estimated glomerular ﬁltration rate. T1, tertile 1; T2, tertile 2; T3, tertile 3.
* p < 0.05 versus T1.
** p < 0.001 versus T1, T2.
Fig. 2. Kaplan–Meier curve analysis of the primary endpoint. The ﬁgure shows the
probability of surviving major adverse cardiovascular events (MACE) in groups of
patients with aortic stenosis divided by tertiles of plasma high-sensitivity troponin T
levels after aortic valve replacement surgery. Kaplan–Meier curve analysis revealed
a  statistically signiﬁcant difference in the survival probability from the MACE among
the  three groups (log-rank test, 2 = 13.0, p = 0.002). T1, tertile 1; T2, tertile 2; T3,
tertile 3. Solid line, T1; dashed line, T2; broken line, T3.
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Table  4
Summary of cardiovascular events in hs-TnT tertiles.
Event T1 T2 T3
Re-admission due to congestive heart failure 0 1 0
Fatal arrhythmia 0 0 3
All  cause death (cardiac death) 1 (1) 1 (0) 5 (4)






























hs-TnT, high-sensitivity troponin T. Major adverse cardiovascular event (MACE) was
eﬁned as composite events of re-admission to the hospital for congestive heart
ailure, fatal arrhythmia, and all causes of death. T1, tertile 1; T2, tertile 2; T3, tertile 3.
Next, we analyzed the independent factors associated with
ACE. A univariate Cox proportional hazard model analysis
howed that eGFR and hs-TnT tertile were signiﬁcant factors asso-
iated with MACE (Table 5). Then we performed a multivariable
ox analysis with the forced entry method, including the patients’
emographic data and these variables (age, sex, eGFR, and hs-TnT
ertile) as explanatory variables. We  found that eGFR and hs-TnT
ertile were independent factors for predicting MACE (Table 6).
We  analyzed each cardiovascular event by Kaplan–Meier curve
nalysis. We  found that the occurrence of fatal arrhythmia and
ardiac death was signiﬁcantly different among the three groups
2 = 6.85, p = 0.03 and 2 = 7.36, p = 0.03, respectively). Fig. 3 shows
he Kaplan–Meier curve analysis of arrhythmic events and cardiac
eath in the groups divided by hs-TnT tertile. A Cox proportional
azard analysis was not conducted because of the small number of
he events.
One patient had cerebral bleeding and two  patients compli-
ated cerebral infarction, however all of these patients had already
able 5
esults of Cox proportional hazard model analysis (univariate).
Variables Hazard ratio (95% CI) p-Value
Age 1.02 (0.95–1.09) 0.64
Male sex 0.78 (0.23–2.63) 0.69
Body mass index 0.92 (0.76–1.11) 0.37
Hypertension 1.36 (0.35–5.24) 0.65
Dyslipidemia 0.27 (0.03–2.01) 0.21
Diabetes mellitus 0.97 (0.26–3.66) 0.96
Smoking 1.38 (0.35–5.43) 0.65
LVEDVI (mL/m2) 1.01 (0.99–1.03) 0.41
LVESVI (mL/m2) 1.01 (0.99–1.03) 0.42
Maximum PG (mmHg) 1.00 (0.97–1.02) 0.74
Mean PG (mmHg) 1.00 (0.96–1.05) 0.90
AVA (cm2) 0.03 (0.001–1.86) 0.10
Post operative maximum PG (mmHg) 0.97 (0.91–1.03) 0.97
Post operative LVEF (%) 0.98 (0.95–1.02) 0.90
Post operative AVA (cm2) 0.04 (0.001–1.97) 0.11
LVMI (g/m2) 1.00 (0.99–1.02) 0.68
LVEF (%) 0.98 (0.94–1.02) 0.34
hs-CRP (ng/mL) 1.22 (0.47–3.13) 0.68
eGFR (mL/min/1.73 m2) 0.97 (0.95–0.99) 0.001
hs-TnT tertile 4.37 (1.53–12.5) 0.006
5% CI, 95% conﬁdence interval; LVEDVI, left ventricular end-diastolic volume index;
VESVI, left ventricular end-systolic volume index; PG, pressure gradient through
ortic valve; AVA, aortic valve area; LVMI, left ventricular mass index; LVEF, left
entricular ejection fraction; hs-CRP, high-sensitivity C-reactive protein; eGFR, esti-
ated glomerular ﬁltration rate; hs-TnT: high-sensitivity troponin T. hs-CRP level
as  logarithmically transformed because of a non-parametric distribution.
able 6
esults of Cox proportional hazard model analysis (multivariate).
Variables Hazard ratio (95% CI) p-Value
Age 1.01 (0.94–1.08) 0.90
Male sex 0.60 (0.17–2.14) 0.43
eGFR (mL/min/1.73 m2) 0.98 (0.96–1.00) 0.04
hs-TnT tertile 3.71 (1.16–11.9) 0.03
5% CI, 95% conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; hs-TnT,
igh-sensitivity troponin T.
Fig. 3. Kaplan–Meier curve analysis of cardiovascular events. (A) Survival prob-
ability from fatal arrhythmia. The incidence of fatal arrhythmia was signiﬁcantly
different among the three groups divided by tertiles of plasma high-sensitivity tro-
ponin T levels after aortic valve replacement surgery (2 = 6.85, p = 0.03). (B) Survival
probability from cardiac death. The incidence of cardiac death was signiﬁcantly dif-
ferent among the three groups (2 = 7.36, p = 0.03). T1, tertile 1; T2, tertile 2; T3,
tertile 3. Solid line, T1; dashed line, T2; broken line, T3.
showed heart failure before the onset of stroke. Thus any throm-
boembolic events were not included in the present study.
Discussion
In this study we explored whether preoperative plasma cardiac
troponin T levels were associated with MACE during the follow-up
of severe AS patients who  underwent AVR. The preoperative hs-TnT
level was an independent predictor of MACE in patients with severe
AS after the surgery. In particular, hs-TnT might be a predictor for
the occurrence of fatal arrhythmia and cardiac death.
A recent high-sensitivity assay has shown that cardiac tro-
ponin levels were elevated in response to cardiovascular diseases
and provide important prognostic information. The increased diag-
nostic and prognostic accuracy of the hs-TnT assay versus the
conventional troponin T assay has recently been reported in several
groups of patients with cardiovascular diseases such as subclini-
cal cardiovascular diseases [16], heart failure [12], and acute [22]
and stable [15] coronary artery diseases. Interestingly, hs-TnT lev-
els were found to predict future heart failure in stable coronary
artery disease [15]. The mechanisms responsible for the release of
low levels of cardiac troponin T could include transient, clinically
silent ischemic episodes and small-vessel occlusions; inﬂammatory
processes; cardiomyocyte apoptosis; reduced renal clearance; and
increased myocardial strain due to pressure or volume overload.
Stenosis of aortic valve increases pressure afterload and ventri-
cular wall stress, resulting in pressure overload to the left ventricle.
Indeed, the strong association between left ventricular mass and
hs-TnT levels is also in line with experimental and clinical works
showing the increased production of troponin T in human and rat




































































[46 T. Saito et al. / Journal of 
een with left ventricular hypertrophy (LVH) may  be the result of
yocardial ischemia due to a supply/demand mismatch in hyper-
rophied myocytes [24]. In our study, we found a signiﬁcant positive
orrelation between plasma hs-TnT and NT-pro BNP, suggesting
hat hs-TnT is associated with cardiac overload.
One potential mechanism for increased MACE may  be suscepti-
ility for arrhythmia. Fibrosis can serve as a structural substrate for
rrhythmia in patients with dilated cardiomyopathy and myocar-
ial infarction has been linked to an increased incidence of
rrhythmia and sudden cardiac death [25]. In patients with AS
nd concurrent LVH, ﬁbrosis is also a common pathologic alter-
tion [26]. Dweck et al. reported that myocardial ﬁbrosis using
ate gadolinium enhancement (LGE) of cardiac magnetic resonance
maging (MRI) was related to prognostic signiﬁcance in AS [27].
imilarly, LGE in cardiac MRI  has been reported to predict cardiac
vents in hypertrophic cardiomyopathy [28]. These results suggest
hat the ﬁbrosis of myocardium might involve arrhythmogenic sub-
trates. The elevation of plasma troponin T levels might reﬂect the
icro-ischemia and degradation of cardiac myocytes and progres-
ion of myocardial ﬁbrosis. Similar to hs-TnT, circulating tenascin
 has been reported to predict heart failure in patients with hyper-
rophic cardiomyopathy [29]. The development of these speciﬁc
iomarkers for cardiovascular disease is needed for prevention of
ajor adverse events.
Røsjø et al. reported that hs-TnT could be a marker to predict
he prognosis of AS in 57 patients [30]. They observed 30 patients
53%) patients who underwent AVR surgery and the natural course
n the remaining 27 patients. In our study, all of the subjects under-
ent AVR and we clearly demonstrated that the hs-TnT could be a
rognostic marker after AVR in patients with severe AS. Together
ith hs-TnT, eGFR was an independent factor to predict MACE in
atients with AS. Although plasma levels of troponin T increase
n patients with renal failure, we found that these two parame-
ers were independently associated with cardiovascular events in
S patients. Precisely how these parameters are associated with
ardiac events after AVR should be elucidated.
In conclusion, preoperative plasma hs-TnT levels could be a
ovel biomarker for predicting MACE in patients with severe AS
ost-AVR. Further study is needed to clarify the precise role of
s-TnT in the pathology of severe AS.
tudy limitations
Our study has several limitations. First, we measured the level
f hs-TnT before AVR. It might be useful to follow the changes in
lasma hs-TnT levels after AVR to provide more information about
he relation between hs-TnT and MACE in severe AS patients. Sec-
nd, our study had a relatively small number of patients and was  a
ingle-center study. However, a single-center study guarantees the
ssential uniformity in patient selection, surgical techniques, and
ostoperative care. Third, the incidence of bicuspid aortic valves
as over half of the total subjects. We  still do not know the rea-
on. Because the etiology of AS might affect the clinical outcome,
his point should be taken into account for the interpretation of our
ata. Further study is needed with a larger population to conﬁrm
he signiﬁcance of hs-TnT in these events.
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